Journal of Hematology & Thromboembolic Diseases
Open Access

Hydrogen Sulfide in Hematologic Malignancies: Resolving Its Dual Role and Therapeutic Potential

Judson Torres^{* *}Correspondence: Judson Torres, Department of Immunology, University of Bologna, Bologna, Italy, Email:

Author info »

Description

Hydrogen Sulfide (H₂S) is increasingly recognized for its complex role in various biological processes, particularly in the context of hematologic malignancies [1]. This article explores the impact of H₂S on these cancers, focusing on its mechanisms of action, therapeutic potential, and the dual nature of its effects. Hematologic malignancies including leukemia, lymphoma, and multiple myeloma, represent a significant challenge in oncology due to their complex biology and often poor prognosis [2-4]. Recent research has highlighted the importance of gaseous signaling molecules, particularly H₂S, in the pathophysiology of these cancers. H₂S is known to influence numerous cellular processes, including apoptosis, proliferation, and angiogenesis, making it a critical player in cancer biology. H₂S is an endogenous gasotransmitter produced in mammalian tissues, primarily through the enzymatic activity of Cystathionine β- Synthase (CBS), Cystathionine γ-lyase (CSE), and 3- Mercaptopyruvate Sulfurtransferase (3-MST) [5]. It plays important role in cellular signaling, influencing various physiological and pathological processes.

Mechanism of action

Cell proliferation and survival: H₂S has been shown to promote the proliferation of cancer cells, particularly in hematologic malignancies [6-8]. It activates several signaling pathways, including the Akt and NF-kB pathways, which are important for cell survival and growth.

Apoptosis regulation: H₂S can inhibit apoptosis in cancer cells, contributing to tumor growth and resistance to therapy. This anti-apoptotic effect is mediated through the modulation of various pro- and anti-apoptotic proteins

Angiogenesis: H₂S influences the formation of new blood vessels, a process essential for tumor growth and metastasis. By promoting angiogenesis, H₂S facilitates nutrient and oxygen supply to tumors, enhancing their growth potential

Metabolic reprogramming: Cancer cells often undergo metabolic changes to support rapid growth. H₂S plays a role in this metabolic reprogramming, affecting pathways related to glycolysis and oxidative phosphorylation.

H₂S in hematologic malignancies

In leukemia, particularly Acute Myeloid Leukemia (AML), elevated levels of H₂S have been associated with poor prognosis [9]. Studies indicate that H₂S promotes the proliferation of leukemic cells and contributes to their resistance to chemotherapy. Targeting H₂S signaling pathways may provide a novel therapeutic strategy for overcoming resistance in AML [10]. H₂S also plays a significant role in lymphomas, where it has been implicated in promoting tumor growth and survival. In particular, the modulation of H₂S levels can influence the tumor microenvironment, affecting immune cell infiltration and function, which are critical for lymphoma progression. In multiple myeloma, H₂S has been shown to enhance cell survival and proliferation through the activation of the NF-kB pathway [11]. This pathway is often dysregulated in myeloma, leading to increased cell survival and chemoresistance. Research suggests that H₂S donors may enhance the efficacy of existing therapies by sensitizing myeloma cells to treatment.

H₂S donors in cancer therapy

H₂S donors, compounds that release H₂S in a controlled manner, are being explored as potential therapeutic agents. These donors can mimic the physiological effects of H₂S, potentially restoring normal signaling pathways disrupted in cancer cells [12-14].

Combination therapies: Combining H₂S donors with traditional chemotherapeutics may enhance treatment efficacy. For instance, studies have shown that H₂S donors can sensitize cancer cells to chemotherapeutic agents, leading to improved outcomes

Targeting H₂S pathways: Inhibiting the enzymes responsible for H₂S production may also be a viable strategy. By reducing H₂S levels in cancer cells, it may be possible to induce apoptosis and inhibit tumor growth.

Clinical trials: Ongoing clinical trials are investigating the safety and efficacy of H₂S donors in various malignancies, including hematologic cancers. These studies aim to establish optimal dosing regimens and identify patient populations that may benefit most from H₂S-targeted therapies

Challenges and future directions

Despite the promising role of H₂S in cancer therapy, several challenges remain [15]. The complexity of H₂S signaling, including its concentration-dependent effects, necessitates a nuanced approach to therapy.

Understanding concentration effects: Low concentrations of H₂S may have protective effects, while high concentrations can be cytotoxic. This duality complicates the development of H₂Sbased therapies

Identifying biomarkers: Identifying biomarkers that predict response to H₂S modulation could enhance the precision of therapies targeting this pathway.

Long-term effects: The long-term effects of H₂S modulation on normal tissues and potential side effects need thorough investigation to ensure patient safety

Conclusion

Hydrogen sulfide is a key player in the biology of hematologic malignancies, influencing critical processes such as cell proliferation, apoptosis, and angiogenesis. Its dual role as both a promoter and inhibitor of cancer progression presents unique opportunities for therapeutic intervention. Ongoing research into H₂S donors and inhibitors holds promise for developing novel treatment strategies that could improve outcomes for patients with hematologic cancers. As our understanding of H₂S biology deepens, it may pave the way for innovative approaches to combat these challenging diseases. This article outlines the multifaceted role of hydrogen sulfide in hematologic malignancies, emphasizing its potential as a therapeutic target while acknowledging the complexities involved in its modulation. Further research is essential to fully harness the therapeutic potential of H₂S in oncology.

References

1. Amod A. The place of sulfonylureas in guidelines: Why are there differences?. Diabetes Ther. 2020;11:5-14.

   [Crossref] [Google Scholar] [PubMed]

2. Bhamre Vaibhav G, Deore Pranjal D, Amrutkar Rakesh D, Patil Vinod R. Polyphenols: The interactions with CYP 450 isoenzymes and effect on pharmacokinetics of drugs. Curr Trends Pharm Pharm Chem. 2022;4:13-23.

   [Google Scholar]

3. Cronin P, Joyce SA, O’Toole PW, O’Connor EM. Dietary fibre modulates the gut microbiota. Nutrients. 2021;13(5):1655.

   [Crossref] [Google Scholar] [PubMed]

4. Das AK, Saboo B, Chawla R, Aravind SR, Rajput R, Singh AK, et al. Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach. Int J Diabetes Dev Ctries. 2023;43(6):856-874.

   [Crossref] [Google Scholar] [PubMed]

5. Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, et al. Mechanisms of CYP450 inhibition: Understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics. 2020;12(9):846.

   [Crossref] [Google Scholar] [PubMed]

6. Gowda NN, Siliveru K, Prasad PV, Bhatt Y, Netravati BP, Gurikar C. Modern processing of Indian millets: A perspective on changes in nutritional properties. Foods. 2022;11(4):499.

   [Crossref] [Google Scholar] [PubMed]

7. Hassan ZM, Sebola NA, Mabelebele M. The nutritional use of millet grain for food and feed: a review. Agric Food Secur. 2021;10:1-4.

   [Crossref] [Google Scholar] [PubMed]

8. Kang P, Cho CK, Jang CG, Lee SY, Lee YJ, Choi CI, et al. Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects. Arch Pharm Res. 2023;46(5):438-447.

   [Crossref] [Google Scholar] [PubMed]

9. Lee SH, Park SY, Choi CS. Insulin resistance: From mechanisms to therapeutic strategies. Diabetes Metab J. 2022;46(1):15-37.

   [Crossref] [Google Scholar] [PubMed]

10. Mikov M, Đanić M, Pavlović N, Stanimirov B, Goločorbin-Kon S, Stankov K, et al. Potential applications of gliclazide in treating type 1 diabetes mellitus: Formulation with bile acids and probiotics. Eur J Drug Metab Pharmacokinet. 2018;43:269-280.

    [Crossref] [Google Scholar] [PubMed]

11. Pei J, Umapathy VR, Vengadassalapathy S, Hussain SF, Rajagopal P, Jayaraman S, et al. A review of the potential consequences of pearl millet (Pennisetum glaucum) for diabetes mellitus and other biomedical applications. Nutrients. 2022;14(14):2932.

    [Crossref] [Google Scholar] [PubMed]

12. Rama Narsimha Reddy A, Kumar V. B. Effect of Valsartan on Pharmacokinetics and Pharmacodynamics of Gliclazide in Diabetic Rats. Curr Res Cardiovas Pharmacol. 2017;6:22-28.

    [Google Scholar]

13. Saini S, Saxena S, Samtiya M, Puniya M, Dhewa T. Potential of underutilized millets as Nutri-cereal: an overview. J Food Sci Technol. 2021:1-3.

    [Crossref] [Google Scholar] [PubMed]

14. Sami W, Ansari T, Butt NS, Ab Hamid MR. Effect of diet on type 2 diabetes mellitus: A review. International journal of health sciences. 2017;11(2):65.

    [Crossref] [Google Scholar] [PubMed]

15. Shao H, Ren XM, Liu NF, Chen GM, Li WL, Zhai ZH, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. J Clin Pharm Ther. 2010;35(3):351-360.

    [Crossref] [Google Scholar] [PubMed]